Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma

Annals of Oncology

Volumn 17, Issue 2, 2006, Pages 304-312

  Steel, J L ^a   Eton, D T ^b   Cella, D ^b   Olek, M C ^a   Carr, B I ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Clinical significance; Functional Assessment of Cancer Therapy Hepatobiliary; Health related quality of life; Hepatobiliary carcinoma; Minimally important difference

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; CHLOROTRIANISENE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; YTTRIUM 90;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DAILY LIFE ACTIVITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ETHNOLOGY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEPATOBILIARY SYSTEM CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; QUALITY OF LIFE; RATING SCALE; RELIABILITY; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 31544473514     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj072     Document Type: Article

References (36)

1. Harrison TJ. Viral hepatitis and primary liver cancer. In Arrand JR, Harper DR (eds): Viruses and Human Cancer. Oxford: BIOS Scientific Publishers Limited 1998.
2. Edwards BK, Brown ML, Wingo PA et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005; 97: 1407-1427.
3. Llovet JM, Bruix J. Systematic review of randomized trial for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-442.
4. Tinchet JC, Ganne-Carrie N, Beaurant M. Review article: Infra-arterial treatments in patients with hepatocellular carcinoma. Aliment Pharmacol Ther 1996; 7 (Suppl 2): 111-118.
5. Camma C, Schepis F, Orlando A et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials. Radiology 2000; 224: 47-54.
6. Geschwind JF, Ramsey D, Choti M et al. Chemoembolization of hepatocellular carcinoma: Results of a meta-analysis. Am J Clin Oncol 2003; 26: 344-349.
7. Kantz ME, Harris WJ, Levitsky K et al. Medical Outcomes Study Short Form-36 - "condition specific". Methods for assessing condition-specific and generic functional status outcomes after total knee replacement. Med Care 1992; 30: MS240-MS252.
8. Bergman B, Aaronson NK, Ahmedzai S et al. EORTC Core Quality of Life Questionnaire - Lung Cancer-13. The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 1994; 30A: 635-642.
9. Cella DF, Tulsky DS, Gray G et al. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 1993; 11: 570-579.
10. Heffernan N, Cella D, Webster K et al. Measuring health-related quality of life in patients with hepatobiliary cancers: The Functional Assessment of Cancer Therapy-Hepatobiliary questionnaire. J Clin Oncol 2002; 20: 2229-2239.
11. Steel JL, Carr BI, Baum A. Quality of life in patients diagnosed with primary hepatocellular carcinoma: Hepatic arterial infusion of Cisplatin versus 90-Yttrium microspheres (Therasphere®). Psychooncology 2004; 13: 73-79.
12. Carr BI. Phase II study of arsenic trioxide in patients with unrectable metastatic hepatocellular carcinoma. National Cancer Institute Clinical Trials Protocol ID PCI-04-06060. http://www.cancer.gov/search/ResultsClinicalTrials.aspx? protocolsearchid=1640831&sort=4&page=2&batch-size=10
13. Carr BI. Phase II Study of hepatic arterial infusion of yttrium 90 glass microspheres (Therasphere) with unresectable hepatocellular carcinoma. National Cancer Institute Protocol ID PCI-04128. http://www.cancer.gov/search/ResultsClinicalTrials.aspx? protocolsearchid=1640831&sort=4&page=2&batch-size=10
14. Carr BI. A research study to treat patients with advanced hepatocellular carcinoma. National Cancer Institute Protocol ID 11546. http://www.cancer.gov/search/ResultsClinicalTrials.aspx? protocolsearchid=1860746 (November 2005, date last accessed).
15. Guyatt GH, Osoba D, Wu AW et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002; 77: 371-383.
16. Yost KJ, Eton DT. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Eval Health Prof 2005; 28: 172-191.
17. Eton DT, Cella D, Yost KJ et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 2004; 57: 898-910.
18. Cohen J. Statistical Power Analysis for Behavioral Sciences. Hillsdale, NH: Lawrence Erlbaum 1988.
19. Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical significance in evaluating intraindividual changes in health-related quality of life. Med Care 1999; 37: 469-478.
20. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intraindividual changes in health-related quality of life. J Clin Epidemiol 1999; 52: 861-873.
21. Steel JL, Geller DA, Carr BI. Proxy ratings of health related quality of life in patients with hepatocellular carcinoma. Qual Life Res 2005; 14: 1025-1033.
22. Yount S, Cella D, Webster K et al. Assessment of patient-reported clinical hepatobiliary cancers: The FACT Hepatobiliary Symptom Index. J Pain Symptom Manage 2002; 24: 32-44.
23. Dancey J, Zee B, Osoba D et al. Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res 1997; 6: 151-158.
24. Hwang SS, Scott CB, Chang VT et al. Prediction of survival for advanced cancer patients by recursive portioning analysis: Role of Karnofsky performance status, quality of life, and symptoms distress. Cancer Invest 2004; 22: 678-687.
25. Llobera J, Eseva M, Rifa J et al. Terminal cancer duration and prediction of survival time. Eur J Cancer 2000; 36: 2036-2043.
26. Toscani P, Brunelli C, Miccinesi G et al. Predicting survival in terminal cancer patients: Clinical observation or quality of life evaluation. Palliat Med 2005; 19: 220-227.
27. Tamburini M, Brunelli C, Rosso S, Ventafridda V. Prognostic value of quality of life scores in terminal cancer patients. J Pain Symptom Manage 1996; 11: 32-41.
28. Peng SY, Ou YH, Chen WY et al. Abberrant expressions of annexin A10 isoform, osteopontin and alpha-fetoprotein at chromosome 4q cooperatively contribute to progression and poor prognosis of hepatocellular carcinoma. Int J Oncol 2005; 26: 1053-1061.
29. Yoon SK, Lim NK, Ha SA et al. The human cervical cancer oncogene protein is a biomarker for human hepatocellular carcinoma. Cancer Res 2004; 64: 5424-5441.
30. Farinati F, Salvagnini M, de Maria M et al. Unresectable hepatocellular carcinoma: A prospective controlled trial with tamoxifen. J Hepatol 1990; 11: 297-301.
31. Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropietic agents: A review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003; 14: 511-519.
32. Vaupel P, Mayer A. Hypoxia and anemia: Effects on tumor biology and treatment resistance, Transfus Clin Biol 2005; 12: 5-10.
33. Knight K, Wade S, Balducci L. Prevalence of outcomes of anemia in cancer: A systematic review of the literature. Am J Med 2004; 116: 11S-26S.
34. McHorney CA, Tarlov AR. Individual-patient monitoring in clinical practice: Are available health status surveys adequate? Qual Life Res 1995; 4: 293-307.
35. Beckerman H, Roebroeck ME, Lankhorst GJ et al. Smallest real difference, a link between reproducibility and responsiveness. Qual Life Res 2001; 10: 571-578.
36. Blazeby JM, Currie E, Zee BCY et al. Development of a questionnaire module to supplement the EORTC QLQ-30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18.